



NMR Spectroscopy Hot Paper

How to cite: *Angew. Chem. Int. Ed.* **2020**, 59, 23496–23499

International Edition: doi.org/10.1002/anie.202009479

German Edition: doi.org/10.1002/ange.202009479

# Non-Stationary Complementary Non-Uniform Sampling (NOSCO NUS) for Fast Acquisition of Serial 2D NMR Titration Data

Javier A. Romero, Ewa K. Nawrocka, Alexandra Shchukina, Francisco J. Blanco, Tammo Diercks, and Krzysztof Kazimierczuk\*

**Abstract:** NMR spectroscopy offers unique benefits for ligand binding studies on isotopically labelled target proteins. These benefits include atomic resolution, direct distinction of binding sites and modes, a lowest detectable affinity limit, and function independent setup. Yet, retracing protein signal assignments from apo to holo states to derive exact dissociation constants and chemical shift perturbation amplitudes (for ligand docking and structure-based optimization) requires lengthy titration series of 2D heteronuclear correlation spectra at variable ligand concentration that may exceed the protein's lifetime and available spectrometer time. We present a novel method to overcome this critical limitation, based on non-stationary complementary non-uniform sampling (NOSCO NUS) combined with a robust particle swarm optimization algorithm. We illustrate its potential in two challenging studies with very distinct protein sizes and binding affinities, showing that NOSCO NUS can reduce measurement times by an order of magnitude to make such highly informative NMR titration studies more broadly feasible.

**S**olution state NMR spectroscopy is a most powerful analytical technique to study molecular interactions with atomic resolution, down to the lowest affinities ( $K_A \geq 10^2 \text{ M}^{-1}$ ), without a function-specific set-up nor risk of bias from biochemical side reactions.<sup>[1]</sup> Thus, NMR can greatly help to elucidate protein function, by identifying even weakly interacting partners, their pertaining binding sites, and the functional groups involved in the molecular interaction, and is now a preferred technique for sound and unbiased studies of multifaceted protein/protein interactions. With its unique

combination of strengths, NMR is furthermore employed by pharmaceutical industry to access novel ligand classes, most efficiently by screening a manageable library of chemically diverse molecular fragments<sup>[2]</sup> that typically bind too weakly for detection by any other technique. By simultaneously reporting on affinity and atomic details of interaction, NMR then helps to elucidate structure–activity relationships<sup>[3]</sup> and guide the iterative structure-based optimization<sup>[4]</sup> into more complex, specific, high-affinity ligands (structure-based drug design, SBDD). This powerful NMR application requires large amounts of isotopically labelled (<sup>15</sup>N or <sup>13</sup>C) target protein and long measurement times to record well-resolved heteronuclear 2D correlation spectra of the protein, where the signals of amino acids affected by ligand binding gradually shift or disappear with increasing ligand concentration. The time exigency is exacerbated by the need to record full titration series to determine the affinity constant, retrace signal assignments from the apo to holo state, and quantify the chemical shift perturbation (CSP) amplitude<sup>[5,6]</sup> of individual signals as the most accurate directly accessible NMR constraint for ligand docking (e.g., by HADDOCK<sup>[7]</sup>) and structure-based ligand optimization. Here we present a new method to massively speed up such exhaustive interaction studies without loss of any information. Complete titration series of 2D protein NMR spectra can, thus, be recorded within less than a day, making them more broadly applicable, e.g., in industrial SBDD processes, or for proteins with limited lifetime.

The critical information on molecular dissociation constants,  $K_D$ , and chemical shift perturbation (CSP) amplitudes,  $\Delta\nu$ , can be derived by individually fitting the correlated signal

[\*] Dr. J. A. Romero, E. K. Nawrocka, Assist. Prof. K. Kazimierczuk

Centre of New Technologies  
University of Warsaw  
Banacha 2C, 02-097, Warsaw (Poland)  
E-mail: k.kazimierczuk@cent.uw.edu.pl

E. K. Nawrocka  
Faculty of Chemistry, University of Warsaw  
Pasteura 1, 02-093 Warsaw (Poland)

Dr. A. Shchukina  
Faculty of Chemistry, Biological and Chemical Research Centre,  
University of Warsaw  
Zwirki i Wigury 101, 02-089 Warsaw (Poland)

Dr. F. J. Blanco  
Structural and Chemical Biology Department, Centro de Investigaciones Biológicas, CIB-CSIC  
28040 Madrid (Spain)

Dr. T. Diercks

CIC bioGUNE  
Parque Tecnológico de Bizkaia, Ed. 800, 48160-Derio (Spain)

Supporting information (video illustrating the iterative NOSCO parameter optimization process using PSO. Comparison of spectral sparsity for SH3 and PCNA. Results from the separate NOSCO repeats underlying Figure 3. Principles of multidimensional NMR signal sampling. Results of combined NOSCO-CS reconstruction of undersampled data. Description of the particle swarm optimization (PSO) algorithm and processing scripts. Plots of peak heights in PCNA/p12 spectra) and the ORCID identification number(s) for the author(s) of this article can be found under:  
<https://doi.org/10.1002/anie.202009479>.

© 2020 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

frequencies, observed in the 2D protein NMR spectra of a titration series, to the equation [Eq. (1)]:


$$\nu_1 = \nu_{1,0} + f(x, K_D) \cdot \Delta\nu_1 \quad (1)$$

where [Eq. (2)]

$$f(x, K_D) = \frac{K_D + (1+x)c_p - \sqrt{(K_D + (1+x)c_p)^2 - 4c_p^2 x}}{2c_p} \quad (2)$$

$\nu_1$  is the observed chemical shift ( $I = {}^{15}\text{N}$  or  ${}^1\text{H}$ ),  $\nu_{1,0}$  is the pertaining reference chemical shift in the absence of ligand;  $\Delta\nu_1$  is the maximal CSP amplitude due to ligand binding;  $x = c_L/c_p$  is the ligand to protein molar ratio;  $c_p$  is the total protein concentration.

NMR frequency sampling in an indirect time dimension is a lengthy process (fundamental reasons described in SI). Here we propose a method for complementary non-uniform sampling (NUS) of entire titration series of 2D  ${}^1\text{H}$ - ${}^{15}\text{N}$  HSQC spectra within less time even than required for a *single* conventional spectrum. For this we sample the indirect  $t_1$  ( ${}^{15}\text{N}$ ) dimension as in a standard NUS experiment, yet with complementary sampling schedules for the different titration points such that each ligand-to-protein ratio,  $x$ , is sampled for a unique set of  $t_1$  times (Figure 1). A full grid of 256  $t_1$  increments in a titration series with 8 different  $x$  ratios would, thus, be sampled in 8 complementary schedules of 32 points. The amount of data to be acquired could be further



**Figure 1.** The concept of non-stationary complementary (NOSCO) sampling of 2D NMR spectra in titration series and signal processing. A reference spectrum is measured separately (with or without NUS) before adding ligand. Titration spectra are then sampled at different ligand-to-protein ratios ( $x$ ) and with complementary NUS schedules, where  $x$  acts as a third pseudo dimension in the resulting pseudo-3D time domain data matrix. The combination of signals and subsequent Fourier transform produces a single 2D correlation spectrum in which signals appear broadened if they experience strong CSP during the titration series (red contours). NOSCO processing effectively refocuses such non-stationary signals (green contours) into their corresponding reference signal (black contours).

reduced by combination with compressed sensing (CS) reconstruction.<sup>[8,9]</sup> The various NUS 2D time-domain data of a titration series can be combined into a 3D matrix and co-processed to yield a single 2D HSQC spectrum, which represents the projection along the third *pseudo* dimension encoding the ligand-to-protein ratio,  $x$ . While signals unaffected by the added ligand maintain their position and shape (provided that a possible dilution effect is compensated for by appropriate intensity scaling), signals that shift strongly (i.e. show large CSP) appear smeared out and broadened due to the superposition of their variable positions in the different underlying 2D spectra of the titration series. The line shape modulation of such signals with strong CSP was described in detail in our previous work.<sup>[10]</sup> A well-separated NMR signal in the co-processed 2D spectrum of a full titration series can be mathematically expressed (neglecting relaxation) as [Eq. (3)]:

$$S_{\text{NS}}(x(t_1), t_1, t_2) = A(x(t_1)) \cdot \exp(i2\pi\nu_{\text{N}}(x(t_1))t_1 + i2\pi\nu_{\text{H}}(x(t_1))t_2) \quad (3)$$

$S_{\text{NS}}$  is a *non-stationary* signal<sup>[10]</sup> if its correlated frequencies  $\nu_{\text{N}}$  and  $\nu_{\text{H}}$  change with the ligand-to-protein ratio  $x$ , which ultimately depends on the indirect sampling time  $t_1$  via the chosen NUS schedule.  $A(x(t_1))$  represents a possible signal amplitude scaling by dilution. With the proposed non-stationary *complementary* (NOSCO) NUS schedule proposed above, the  $x(t_1)$  dependence becomes straightforward, unambiguous, and traceable.

A 2D time-domain signal  $S_{\text{NS}}(t_1, t_2)$  can be obtained by Inverse Fourier Transform (IFT) of a single-peak spectral region containing only its frequency-domain counterpart,  $\tilde{S}_{\text{NS}}(\nu_1, \nu_2)$ . The single-site binding model [Eq. (1)] predicts that  $S_{\text{NS}}$  [Eq. (3)] is the product of a stationary component with frequencies  $\nu_{1,0}$  and a non-stationary component depending on  $f(x(t_1), K_D)$  as well as the CSP amplitude  $\Delta\nu_1$ . The time-domain counterpart of each peak in a co-processed titration series spectrum acquired with complementary NOSCO sampling therefore is the product of a regular (stationary) signal from the reference sample (without ligand) and a non-stationary factor (dependent on the ligand-to-protein ratio) that always causes signal broadening and attenuation.

The idea behind NOSCO processing is to remove the *non-stationary* factor for each *smeared* peak, thus refocusing it into the sharp reference signal with a concomitant increase in intensity (Figure 1). For this, NOSCO searches a combination of non-stationarity parameters  $\{\Delta\nu_{\text{N}}, \Delta\nu_{\text{H}}, K_D\}$  that produces a correction signal  $S_C$  for each *smeared* 2D time-domain signal  $S_{\text{NS}}$  with minimal difference to its reference signal [Eq. (4)]:

$$\arg \min_{\Delta\nu_{\text{N}}, \Delta\nu_{\text{H}}, K_D} |\max\{\text{FT}[S_{\text{NS}} \cdot S_C]\} - \max\{\text{FT}[S_P]\}| \quad (4)$$

FT is the Fourier Transform of the time domain product ( $S_{\text{NS}} \cdot S_C$ ),  $\max$  is the maximum value of the transform (the peak height),  $S_P$  is the reference signal in an HSQC spectrum acquired separately (with or without NUS) before ligand addition. The correction signal  $S_C$  depends on the adjustable CSP amplitudes ( $\Delta\nu_{\text{N}}$ ,  $\Delta\nu_{\text{H}}$ ) and dissociation constant ( $K_D$ ) as follows [Eq. (5)]:

$$S_c = \exp(-i2\pi \cdot f(x(t_1), K_D) \cdot (\Delta\nu_N \cdot t_1 + \Delta\nu_H \cdot t_2)) \quad (5)$$

As Equation (4) may have several local minima, its global minimization requires to efficiently scan a vast parameter space  $\{\Delta\nu_N, \Delta\nu_H, K_D\}$  for each selected *smear*ed peak. For this purpose, we implemented a Particle Swarm Optimization (PSO) algorithm<sup>[11]</sup> that can simultaneously optimize the parameter triplet  $\{\Delta\nu_N, \Delta\nu_H, K_D\}$  without requiring the target function to be smooth, and with robustness against falling into local minima (see SI for more information).


We have applied the proposed NOSCO NUS method to two protein-ligand systems with quite distinct protein sizes, binding constants, signal-to-noise ratios, and spectral dispersions. The first protein, SH3 domain of  $\alpha$ -spectrin, has 60 residues and binds proline-rich peptides by recognizing sequences with a PXXP motif.<sup>[12]</sup> As ligand we used the short p41 decapeptide<sup>[13,14]</sup> and screened  $n_x = 8$  ligand-to-protein ratios  $x$ . NOSCO NUS sampling of the full pseudo 3D data, thus, affords a compaction of the overall measurement time by factor  $n_x = 8$ , given the same overall sampling level as for each individual 2D titration spectrum. At pH 3.5, SH3 binds p41 very weakly ( $K_D = 9$  mM) and, therefore, requires high ligand-to-protein ratios for reliable  $K_D$  determination. The results from conventional fitting of Equation (1) to the observed CSP values of selected SH3 domain signals are shown in Figure 2. Despite the low protein concentration used, no CSP curve reaches near its plateau value, making  $K_D$  determination challenging by any method. On the other hand, the 2D  $^1\text{H}$ - $^{15}\text{N}$  HSQC spectrum of SH3 domain remains rather simple and well-resolved throughout the titration series, despite some clear signal *smearing* in the NOSCO spectrum. This high spectral sparsity facilitates the *undersampling* mode of NOSCO NUS (see above and SI). The second protein, human Proliferating Cell Nuclear Antigen (PCNA), forms a symmetrical homotrimer of 87 kDa that binds many proteins, including the polymerase- $\delta$  p12 subunit. As ligand we used a fragment of p12<sup>[15]</sup> and  $n_x = 6$  ligand-to-protein ratios  $x$ , implying a potential time saving by NOSCO NUS of

at least a factor  $n_x = 6$ . In contrast to the SH3/p41 system, PCNA/p12 binding is stronger ( $K_D = 130$   $\mu\text{M}$ ), close to the limit for biologically relevant interactions, while spectral intensities and sparsity are much lower for PCNA. Therefore, each 2D titration spectrum required 22 h measurement time (vs. 1.5 h for SH3).


Figure 3 shows a comparison of parameters  $\{\Delta\nu_1, \Delta\nu_2, K_D\}$  derived by NOSCO co-processing vs. conventional fitting. For SH3/p41 binding, the processing of NOSCO NUS acquired time-domain data (8-12.5% sampling levels) and averaging over 13 residues yields a  $K_D = (9 \pm 4)$  mM, in full agreement with the conventional method (using 100% sampled 2D spectra). For the PCNA/p12 system, the full time-domain data had been sampled conventionally before,<sup>[15]</sup> from which we constructed a NOSCO NUS matrix by appropriate selection of  $t_1$  data points (6-16.7% sampling levels). Again, the averaged (over 10 residues)  $K_D = (130 \pm 50)$   $\mu\text{M}$  from NOSCO processing agreed fully with the conventionally obtained result, except for an apparently larger error. PSO parameters used were: 1000 particles, 10 iterations, 5 runs (see SI). NOSCO processing took approximately 15 minutes of computation time per selected single-peak spectral region (with 4-fold zero filling in both dimensions separately) running on an Intel(R) Xeon(R) CPU E5-2680 v2 @ 2.80 GHz with 48 GB of RAM and using MATLAB 2015b with Parallel Computing Toolbox.

Figures 2 and 3 show the per residue and averaged  $K_D$  values obtained for both protein/ligand systems by conventional data analysis vs. NOSCO co-processing, respectively. For the SH3/p41 system, 13 signals were suited for both conventional and NOSCO analysis. For the PCNA/p12 system, 22 signals showed sufficient CSP for conventional analysis,<sup>[15]</sup> but high spectral crowding allowed NOSCO analysis only for 10 well resolved signals (i.e. single peak containing spectral regions), which reduced the accuracy of  $K_D$  determination by this method simply due to the fewer data for averaging. Finally, the PCNA/p12 system also shows common signal decrease and broadening during titration (see SI). In contrast to dilution, the effect of such (chemical or conformational) signal broadening is neither uniform nor known a priori and, therefore, cannot be compensated by NOSCO. Yet, our results show that NOSCO processing can provide reasonable results even in these cases.

In summary, we have presented a complementary  $t_1$  sampling schedule to record an entire titration series of 2D experiments as one *pseudo* 3D NOSCO NUS experiment, where the added dimension encodes the variable ligand-to-protein ratio in an unambiguous, traceable manner. Co-processing of such pseudo 3D data produces a single projected 2D spectrum, where signals affected by binding induced CSP appear smeared out. These can be re-focused by dedicated NOSCO processing to extract accurate values for  $K_D$  and the CSP amplitudes that are of great significance,



**Figure 2.** CSP ( $^1\text{H}$ ) versus ligand-to-protein ratio ( $x$ ) for selected signals from 2D  $^1\text{H}$ - $^{15}\text{N}$  correlation spectra. A) p41 binding by SH3; B) p12 binding by PCNA. Curves were obtained by least squares data fitting to Equation (1) and using series of fully sampled 2D spectra (herein called conventional method). Final  $K_D$  values and errors are the averages and standard deviations over all selected signals, respectively.



**Figure 3.** Individual  $K_D$  values (log scale) and CSP amplitudes versus residue. A) p41 binding by SH3; B) p12 binding by PCNA. Blue circles: Results from conventional fitting of individual  $^1\text{H}$ - $^{15}\text{N}$  titration spectra. Red squares: Results from NOSCO co-processing (error bars correspond to the standard deviation from 20 repeats using the same NOSCO time domain data, see Supporting Information). Left: Individual  $K_D$  values, with indication of the average value (identical for both analysis methods) and 95 % confidence interval (green band): CSP amplitudes (in Hz) for  $^{15}\text{N}$  (top) and  $^1\text{H}$  (bottom); the indicated limits of  $\gamma$  axis correspond to the specified parameter boundaries for NOSCO processing.

e.g., for structure based ligand optimization. Currently, the method is limited to a single binding-site model and 2D spectra, but can be extended to other binding models and higher dimensionality.

The overall measurement times for titration series are reduced by an order of magnitude, that is, by the number of ligand-to-protein ratios screened, and may be further reduced by combining NOSCO processing with CS reconstruction (see SI). This may open new and broader applications of NMR titration experiments, e.g., to unstable target proteins (or ligands) and in industrial drug discovery projects.

## Acknowledgements

We are grateful for financial support from the National Science Centre of Poland via the HARMONIA grant (2017/26/M/ST4/01053), the Foundation for Polish Science via the FIRST TEAM program co-financed by the European Union

under the European Regional Development Fund no. (POIR.04.04.00-00-4343/17-00), the Department of Industry, Tourism and Trade of the Government of the Autonomous Community of the Basque Country (Elkartek BG2019), and the Severo Ochoa Excellence Accreditation from MCIU (SEV-2016-0644.). FJB thanks MCIU for grant CTQ 2017-83810-R.

## Conflict of interest

The authors declare no conflict of interest.

**Keywords:** compressed sensing · ligand binding · NMR spectroscopy · non-uniform sampling · titration

- [1] T. Diercks, M. Coles, H. Kessler, *Curr. Opin. Chem. Biol.* **2001**, *5*, 285–291.
- [2] J. Fejzo, C. A. Lepre, J. W. Peng, G. W. Bemis, Ajay, M. A. Murcko, J. M. Moore, *Chem. Biol.* **1999**, *6*, 755–769.
- [3] S. B. Shuker, P. J. Hajduk, R. P. Meadows, S. W. Fesik, *Science* **1996**, *274*, 1531–1534.
- [4] J. Stark, R. Powers, *J. Am. Chem. Soc.* **2008**, *130*, 535–545.
- [5] M. P. Williamson, *Prog. Nucl. Magn. Reson. Spectrosc.* **2013**, *73*, 1–16.
- [6] D. González-Ruiz, H. Gohlke, *J. Chem. Inf. Model.* **2009**, *49*, 2260–2271.
- [7] C. Dominguez, R. Boelens, A. Bonvin, *J. Am. Chem. Soc.* **2003**, *125*, 1731–1737.
- [8] K. Kazimierzczuk, V. Y. Orekhov, *Angew. Chem. Int. Ed.* **2011**, *50*, 5556–5559; *Angew. Chem.* **2011**, *123*, 5670–5673.
- [9] D. J. Holland, M. J. Bostock, L. F. Gladden, D. Nietlispach, *Angew. Chem. Int. Ed.* **2011**, *50*, 6548–6551; *Angew. Chem.* **2011**, *123*, 6678–6681.
- [10] D. Gołowicz, P. Kasprzak, V. Orekhov, K. Kazimierzczuk, *Prog. Nucl. Magn. Reson. Spectrosc.* **2020**, *116*, 40–55.
- [11] J. Kennedy, R. Eberhart, *Proceedings of ICNN'95—International Conference on Neural Networks*, Vol. 4, **1995**, 1942–1948.
- [12] J. T. Nguyen, C. W. Turck, F. E. Cohen, R. N. Zuckermann, W. A. Lim, *Science* **1998**, *282*, 2088–2092.
- [13] S. Casares, E. Ab, H. Eshuis, O. Lopez-Mayorga, N. A. Van Nuland, F. Conejero-Lara, *BMC Struct. Biol.* **2007**, *7*, 22.
- [14] H. M. Berman, T. Battistuz, T. N. Bhat, W. F. Bluhm, P. E. Bourne, K. Burkhardt, Z. Feng, G. L. Gilliland, L. Iype, S. Jain, P. Fagan, J. Marvin, D. Padilla, V. Ravichandran, B. Schneider, N. Thanki, H. Weissig, J. D. Westbrook, C. Zardecki, *Acta Crystallogr. Sect. D* **2002**, *58*, 899–907.
- [15] A. Gonzalez-Magaña, A. I. de Opakua, M. Romano-Moreno, J. Murciano-Calles, N. Merino, I. Luque, A. L. Rojas, S. Onesti, F. J. Blanco, A. De Biasio, *J. Biol. Chem.* **2019**, *294*, 3947–3956.

Manuscript received: July 13, 2020

Accepted manuscript online: August 27, 2020

Version of record online: September 29, 2020